Corpus Intelligence IC Memo — DOCTOR CENTER HOSPITAL MANATI INC. 2026-04-26 05:26 UTC
IC Memo — DOCTOR CENTER HOSPITAL MANATI INC.
Investment Committee Memorandum | PR | 258 beds | Grade C | EBITDA uplift $7.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

DOCTOR CENTER HOSPITAL MANATI INC.

CCN 400118 | nan, PR | 258 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

DOCTOR CENTER HOSPITAL MANATI INC. is a 258-bed safety-net/medicaid heavy in nan, PR with $103.4M in net patient revenue and a 1.6% operating margin. The hospital serves a payer mix of 6.0% Medicare, 37.6% Medicaid, and 56.5% commercial.

Thesis: Undervalued. Our ML models identify $7.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 1.6% to 8.9% (+736bps).

Net Revenue HCRIS$103.4M
Current EBITDA COMPUTED$1.6M
Operating Margin COMPUTED1.6%
Occupancy HCRIS90.6%
Revenue / Bed COMPUTED$401K
Net-to-Gross HCRIS57.7%
Distress Probability ML50.9%

2. Market Context & Competitive Position

61
PR Hospitals
-8.8%
State Median Margin
29
Comparable Hospitals

PR has 61 Medicare-certified hospitals with a median operating margin of -8.8%. The target's margin of 1.6% places it above the state median. Among 29 size-comparable peers (129-516 beds), the median margin is -4.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (129-516), prioritizing same-state peers. 29 hospitals in the comp set.

HospitalStateBedsRevenueMargin
DOCTOR CENTER HOSPITAL MANATI (Target)PR258$103.4M1.6%
AUXILIO MUTUO HOSPITALPR481$232.1M-1.7%
HOSPITAL MENONITA DE CAYEYPR225$186.2M15.0%
SAN LUCAS PONCEPR348$141.1M9.2%
HOSPITAL DR. ALEJANDRO OTEROPR263$129.0M-1.0%
HOSPITAL HIMA SAN PABLO CAGUASPR421$120.1M-23.4%
HOSPITAL MENONITA CAGUAS INCPR232$114.1M6.8%
MAYAGUEZ MEDICAL CENTERPR210$102.8M7.6%
HOSPITAL PAVIA SANTURCEPR156$101.9M-9.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $7.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.2M+210bp18mo
Cost to Collect4.5%2.5%$2.1M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.0M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.3M+122bp9mo
Clean Claim Rate88.0%96.0%$66K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.2M
Cost to Collect
$2.1M
Denial Rate Reduction
$2.0M
A/R Days Reduction
$1.3M
Clean Claim Rate
$66K
Total EBITDA Uplift$7.6M
Current EBITDA$1.6M
+ RCM Uplift+$7.6M
Pro Forma EBITDA$9.2M
Current Margin1.6%
Pro Forma Margin8.9%
WC Released (1x)$4.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$2.5M$86.9M34.50x103.0%
Base (11x exit)10.0x11.0x$2.5M$96.4M38.27x107.3%
Bull Case9.0x11.0x$2.3M$122.3M53.96x122.0%
Bull (12x exit)9.0x12.0x$2.3M$134.1M59.16x126.2%
Bear Case11.0x10.0x$2.8M$48.0M17.33x76.9%
Bear (11x exit)11.0x11.0x$2.8M$53.7M19.39x80.9%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (37.6%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 50.9% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 29 hospitals with 129-516 beds
  • Same-state prioritization (n=30)
  • Comp margins: P25=-19.8% / P50=-4.4% / P75=2.0%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.